ERBC Lyon de-risks novel oncology candidates with our pioneering AVI-tumor platform to empower biotech and pharma partners:

• Generate clinically relevant efficacy data in days, not months, adhering to the highest 3R standards
• Utilize a unique immunocompetent avian embryo model to evaluate immunotherapies in a biologically relevant context
• Accelerate early decision-making for diverse lead candidates, from antibodies and peptides to cell therapies